Welcome to our dedicated page for Entrada Therapeutics SEC filings (Ticker: TRDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Entrada Therapeutics’ SEC disclosures aren’t just numbers—they detail how the company’s EEV™ platform may unlock intracellular targets that traditional medicines miss. Yet decoding R&D expense lines, clinical trial updates, and collaboration milestones in a 300-page 10-K can feel overwhelming. If you’ve searched “Entrada Therapeutics SEC filings explained simply” or wondered how recent 8-K material events tie to Duchenne muscular dystrophy studies, you’re not alone.
Stock Titan bridges that gap. Our AI parses every Entrada Therapeutics quarterly earnings report 10-Q filing, flags cash-runway shifts, and converts scientific jargon into clear language. Receive Entrada Therapeutics Form 4 insider transactions real-time alerts to track when executives buy or sell shares. Need context for a sudden shelf registration? The platform links S-3 details to potential capital raises and provides concise, expert commentary. From the annual report 10-K simplified to each proxy statement executive compensation, you’ll find form-specific summaries, keyword search, and side-by-side comparisons — all updated the moment EDGAR posts.
Use these insights to:
- Monitor Entrada Therapeutics insider trading Form 4 transactions before key readouts
- Compare trial spending across quarters with our “cash used in operations” trend tool
- Spot risk-factor changes the instant they appear in an 8-K
Janus Henderson Group plc reports beneficial ownership of 1,521,281 shares of Entrada Therapeutics common stock, representing 4.0% of the class. The filing states Janus Henderson has no sole voting or dispositive power and shared voting and dispositive power over all reported shares.
The filing identifies certain indirect subsidiaries (including JHIUS, JHIUKL and JHIAIFML) as registered investment advisers furnishing advice to Managed Portfolios and includes a certification that the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Entrada Therapeutics, Inc. (Form 10-Q) — quarter ended June 30, 2025. The company reported $72.5M cash and cash equivalents and $281.5M marketable securities (total $354.0M) and total assets of $448.8M as of June 30, 2025. Total liabilities were $69.3M and accumulated deficit was $189.8M. Shares outstanding: 38,033,970 as of June 30, 2025 (38,037,079 as of July 31, 2025).
Operational and financial results: collaboration revenue was $1.95M for Q2 2025 and $22.51M for the six months ended June 30, 2025 (versus $94.69M and $153.81M in the comparable 2024 periods). R&D expense was $37.88M in Q2 2025 and $69.95M for six months; G&A expense was $10.92M and $21.20M, respectively. Net loss: $43.10M for the quarter and $60.45M for six months (basic net loss per share Q2: $1.04; six months: $1.47).
Corporate developments: first patient dosed in ELEVATE-44-201 and ELEVATE-45-201 initiated; company expects to file for ENTR-601-50 in Q4 2025. Vertex collaboration revenue recognition included a cumulative catch-up adjustment of $12.3M during H1 2025 and the remaining transaction price allocated to unsatisfied obligations was $0.9M at June 30, 2025. The company implemented a ~20% workforce reduction in April 2025 with a related charge of $1.9M. Management states liquidity is sufficient to fund operations into the second quarter of 2027.
Entrada Therapeutics (TRDA) – Form 4 insider transaction summary
Director and 10% owner Dr. Kush Parmar, through two affiliated venture funds, reported open-market sales totaling 125,000 common shares between 27 June and 1 July 2025. The sales were executed at prices ranging from $6.81 to $7.12 per share, generating roughly $0.9-1.2 million in proceeds (exact proceeds depend on final settlement).
- 5AM Ventures V, L.P. sold 92,891 shares across three trades and now owns 3,183,131 shares.
- 5AM Opportunities I, L.P. sold 32,109 shares and now owns 1,100,248 shares.
- The combined position after the transactions is approximately 4.28 million shares, meaning only about 2.8 % of their prior stake was divested.
No derivative securities were involved, and Dr. Parmar continues to disclaim beneficial ownership beyond his pecuniary interest. While insider selling often raises caution among investors, the modest percentage sold and the remaining large holding suggest routine portfolio rebalancing rather than a wholesale exit.
Form 4 filings dated 07/01/2025 disclose that venture–backed funds affiliated with 5AM Venture Management, a 10 % beneficial owner of Entrada Therapeutics (TRDA), executed a three-day program of open-market sales. The entities involved were 5AM Ventures V, L.P. (direct holder) and 5AM Opportunities I, L.P. (indirect holder). The sales were made on 06/27, 06/30 and 07/01 at prices ranging from $6.81 – $7.12 per share.
- Shares sold by 5AM Ventures V: 92,891 shares (55,735 + 18,578 + 18,578) for proceeds of roughly $639k.
- Shares sold by 5AM Opportunities I: 32,109 shares (19,265 + 6,422 + 6,422) for proceeds of roughly $220k.
- Total shares sold: 125,000 shares, representing about 2.8 % of the combined 4.41 million-share position held prior to the first transaction.
After the transactions, 5AM Ventures V holds 3,183,131 shares directly, while 5AM Opportunities I holds 1,100,248 shares indirectly, leaving the 5AM group with an aggregate stake of approximately 4.28 million shares. All reporting persons—5AM Partners V, 5AM Opportunities I (GP), and managing members Dr. Scott M. Rocklage and Andrew J. Schwab—remain classified as 10 % owners. No derivative securities were reported.
The filing signals modest insider selling by a large shareholder following a minor upward move in TRDA’s share price during the period. Although the group maintains a substantial ownership position, the reduction could be interpreted by investors as a slight negative sentiment shift or portfolio rebalancing.
FAQ
What is the current stock price of Entrada Therapeutics (TRDA)?
What is the market cap of Entrada Therapeutics (TRDA)?
